爾康製藥(300267.SZ)2022年度預盈4500萬-6500萬元、同比扭虧為盈
格隆匯1月31日丨爾康製藥(300267.SZ)公佈,預計2022年度歸屬於上市公司股東的淨利潤4500萬元-6500萬元,上年同期為虧損79120.2萬元;扣除非經常性損益後的淨利潤2146萬元-4146萬元,上年同期為虧損80776.95萬元。
業績變動原因如下:1、在醫藥行業改革持續、藥品集採常態化、新冠疫情反覆的背景下,公司圍繞既定戰略目標,緊跟市場情況及時調整經營策略,報吿期內公司主營業務繼續保持穩定的發展態勢。
2、2021年度,基於謹慎性原則,公司對改性澱粉及澱粉囊項目資產組、改性澱粉及澱粉囊系列存貨等相關資產計提減值準備,導致2021年度歸屬於上市公司股東的淨利潤出現虧損。經測算,報吿期重大資產組未發生明顯減值跡象,故計提的資產減值準備較上年度減少。
3、預計報吿期非經常性損益對淨利潤的貢獻金額約2354萬元左右,較去年同期增加697萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.